Mr. Thomas O'Shaughnessy reports

ONCO-INNOVATIONS ENTERS INTO LOI WITH IFOWONCO FOR EXCLUSIVE OPTION AND WORLDWIDE LICENCE TO LAG-3 SMALL-MOLECULE INHIBITOR PROGRAM

Onco-Innovations Ltd. has entered into a non-binding letter of intent with Ifowonco Informatics Inc. as an initial step toward negotiating a definitive agreement that would, if completed, grant Onco an exclusive option relating to Ifowonco's proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3.

The proposed collaboration is intended to combine Ifowonco's novel oral small-molecule immune checkpoint technology with Onco-Innovations' expertise in DNA damage response therapeutics, translational oncology and clinical development. The companies believe the combination of DDR inhibition and LAG-3 blockade could achieve a scientifically compelling strategy with the potential to enhance anti-tumour immune responses across multiple solid tumour indications.

LAG-3 is an immune checkpoint protein involved in regulating T-cell activation. Ifowonco is developing small-molecule compounds intended to inhibit LAG-3 and potentially restore immune activity against cancer cells. The proposed collaboration is aimed at providing a framework for evaluating the LAG-3 program independently and, where supported by preclinical findings, exploring its potential use alongside DNA damage response-based therapeutic approaches.

"Our objective has always been to build a differentiated oncology pipeline by combining innovative science with strategic partnerships. Ifowonco has developed a promising oral small-molecule LAG-3 inhibitor platform that we believe could complement our ONC010 DNA damage response program. We are excited to begin working toward a definitive agreement that could position Onco-Innovations at the intersection of precision oncology and next-generation cancer immunotherapy," said Thomas O'Shaughnessy, chief executive officer of Onco-Innovations.

Unlike currently approved LAG-3 therapies, which are monoclonal antibodies administered intravenously, Ifowonco's program is focused on developing orally available small-molecule inhibitors, offering the potential for greater patient convenience, flexible dosing and combination therapy opportunities. The companies believe that combining LAG-3 inhibition with ONC010's DNA damage response mechanism may provide a synergistic therapeutic approach.

"DNA damage response inhibition and immune checkpoint blockade are increasingly recognized as complementary therapeutic strategies. The scientific rationale supporting the evaluation of ONC010 with LAG-3 blockade is compelling and aligns with our long-term vision of developing innovative combination therapies that may improve outcomes for patients with difficult-to-treat cancers," said Dr. Islam Mohamed, chief medical officer of Onco-Innovations.

About Onco-Innovations Ltd.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company holds an exclusive worldwide licence to patented technology directed to the therapeutic inhibition of PNKP, a novel clinical target in DNA damage response.

We seek Safe Harbor.